20240309_am24_abstract_topic_model

djordan/20240309_am24_abstract_topic_model

20240309_am24_abstract_topic_model is a text classification model from djordan. Use it when you need a label for a piece of text. It is set up for bertopic.

This is a BERTopic model. BERTopic is a flexible and modular topic modeling framework that allows for the generation of easily interpretable topics from large datasets.

Downloads · 30 days

6% of all-time downloads

All-time downloads

133

Public

Repo size

4.2 MB

Likes

Public

Hugging Face

Repo makeup

Click a slice to open those files.

.safetensors4.2 MB · 75%

At a glance

Task: Text Classification
Library: bertopic
Access: Public
Created: Mar 9, 2024
Updated: Mar 9, 2024
SHA: 0da553e8

Try a prompt

Model card

From the Hugging Face model README

20240309_am24_abstract_topic_model

This is a BERTopic model. BERTopic is a flexible and modular topic modeling framework that allows for the generation of easily interpretable topics from large datasets.

Usage

To use this model, please install BERTopic:

pip install -U bertopic

You can use the model as follows:

from bertopic import BERTopic
topic_model = BERTopic.load("djordan/20240309_am24_abstract_topic_model")

topic_model.get_topic_info()

Topic overview

Number of topics: 175
Number of training documents: 8265

<details> <summary>Click here for an overview of all topics.</summary>

</details>

Training hyperparameters

calculate_probabilities: False
language: None
low_memory: False
min_topic_size: 10
n_gram_range: (1, 1)
nr_topics: None
seed_topic_list: None
top_n_words: 10
verbose: True
zeroshot_min_similarity: 0.7
zeroshot_topic_list: None

Framework versions

Numpy: 1.25.2
HDBSCAN: 0.8.33
UMAP: 0.5.5
Pandas: 1.5.3
Scikit-Learn: 1.2.2
Sentence-transformers: 2.6.0.dev0
Transformers: 4.39.0.dev0
Numba: 0.58.1
Plotly: 5.15.0
Python: 3.10.12

Task: Text Classification
Library: bertopic
Created: Mar 9, 2024
Updated: Mar 9, 2024

Topic ID	Topic Keywords	Topic Frequency	Label
-1	Immunotherapy and Tumor Microenvironment - - - -	5	Immunotherapy and Tumor Microenvironment
0	Cancer Survival and Healthcare Access - - - -	3778	Cancer Survival and Healthcare Access
1
Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies - - - -	429	Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies
2	Glioblastoma research and treatment - - - -	186	Glioblastoma research and treatment
3	"3D Organoid Culture in Cancer Research" - - - -	168	3D Organoid Culture in Cancer Research
4	Kras G12C Inhibitors and Resistance - - - -	160	Kras G12C Inhibitors and Resistance
5
Acute Myeloid Leukemia Treatment and Drug Screening - - - -	154	Acute Myeloid Leukemia Treatment and Drug Screening
6	Spatial imaging of tissue microenvironments - - - -	120	Spatial imaging of tissue microenvironments
7	Prostate cancer and AR degradation - - - -	112	Prostate cancer and AR degradation
8	Parp Inhibition and DNA Damage Repair - - - -	110	Parp Inhibition and DNA Damage Repair
9	Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment - - - -	99	Pancreatic Ductal Adenocarcinoma Microenvironment
10	Topoisomerase 1 Inhibitors Adc Development - - - -	92	Topoisomerase 1 Inhibitors Adc Development
11	Hepatocellular Carcinoma Treatment Research - - - -	85	Hepatocellular Carcinoma Treatment Research
12	EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer - - - -	78	EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer
13	Glutamine Metabolism in Cervical Cancer - - - -	76	Glutamine Metabolism in Cervical Cancer
14
"Nanoparticle-based cancer treatment" - - - -	67	Nanoparticle-based cancer treatment
15	Bone metastasis in breast cancer - - - -	56	Bone metastasis in breast cancer
16	Microbiome and Immunotherapy in Cancer - - - -	54	Microbiome and Immunotherapy in Cancer
17	Triple Negative Breast Cancer (TNBC) - - - -	51	Triple Negative Breast Cancer
18
Oral Squamous Cell Carcinoma (OSCC) Research - - - -	48	Oral Squamous Cell Carcinoma Research
19	Melanoma therapy and Braf inhibitors - - - -	46	Melanoma therapy and Braf inhibitors
20	Immunomodulation of Glioblastoma with Sting Agonism - - - -	45	Immunomodulation of Glioblastoma with Sting Agonism
21
"Anticancer mechanisms of natural compounds" - - - -	41	Anticancer mechanisms of natural compounds
22	Renal Cell Carcinoma Subtypes - - - -	41	Renal Cell Carcinoma Subtypes
23
"Liquid Biopsy Using Urine and Plasma Samples" - - - -	40	Liquid Biopsy Using Urine and Plasma Samples
24	Award ceremony speech draft - - - -	39	Award ceremony speech draft
25
TCR-engineered therapy for cancer treatment - - - -	38	TCR-engineered therapy for cancer treatment
26	T-cell engagers for cancer treatment - - - -	38	T-cell engagers for cancer treatment
27	Colorectal cancer research - - - -	37	Colorectal cancer research
28	Obesity and breast cancer - - - -	36	Obesity and breast cancer
29	Ferroptosis in cancer treatment - - - -	36	Ferroptosis in cancer treatment
30	Trop2-targeted ADCs for cancer treatment - - - -	34	Trop2-targeted ADCs for cancer treatment
31	Hippo pathway inhibitors - - - -	34	Hippo pathway inhibitors
32	Immunotherapy in mice - - - -	33	Immunotherapy in mice
33
Clinical trials of immunotherapies - - - -	32	Clinical trials of immunotherapies
34	Immunity checkpoint inhibitors and resistance - - - -	29	Immunity checkpoint inhibitors and resistance
35	Pancreatic cancer research - - - -	29	Pancreatic cancer research
36	Drug combination screening - - - -	28	Drug combination screening
37
Pancreatic Cancer Research - - - -	27	Pancreatic Cancer Research
38	Her2 expression in solid tumors - - - -	26	Her2 expression in solid tumors
39	Smoking-induced lung cancer research - - - -	26	Smoking-induced lung cancer research
40
"Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer" - - - -	26	Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer
41	Prostate cancer research and treatment - - - -	25	Prostate cancer research and treatment
42	Cyclin-dependent kinase 2 inhibition in cancer therapy - - - -	25	Cyclin-dependent kinase 2 inhibition in cancer therapy
43
"Methylation Detection from Cell-Free DNA" - - - -	25	Methylation Detection from Cell-Free DNA
44	Medulloblastoma research and treatment - - - -	25	Medulloblastoma research and treatment
45	Single-cell RNA sequencing and chromatin accessibility analysis - - - -	24	Single-cell RNA sequencing and chromatin accessibility analysis
46
"MTA-PRMT5 Inhibitors for Cancer Treatment" - - - -	24	MTA-PRMT5 Inhibitors for Cancer Treatment
47	Anti-PD-1 therapy in NSCLC - - - -	24	Anti-PD-1 therapy in NSCLC
48	Immunomodulation with IL-18 and PD-1 antagonists - - - -	24	Immunomodulation with IL-18 and PD-1 antagonists
49	RMS and Pax3-Foxo1 Fusion Protein Research - - - -	24	RMS and Pax3-Foxo1 Fusion Protein Research
50
"Chromatin organization and gene regulation in breast cancer" - - - -	24	Chromatin organization and gene regulation in breast cancer
51	Multi-Cancer Early Detection Tests - - - -	23	Multi-Cancer Early Detection Tests
52
Mitochondrial dysfunction in cancer - - - -	23	Mitochondrial dysfunction in cancer
53	Cholangiocarcinoma research and treatments - - - -	23	Cholangiocarcinoma research and treatments
54	Immune cell analysis with cytof - - - -	23	Immune cell analysis with cytof
55
"Circulating Tumor DNA Monitoring in Cancer Treatment" - - - -	23	Circulating Tumor DNA Monitoring in Cancer Treatment
56	Cellular thermal shift assay (CTSA) for target engagement - - - -	22	Cellular thermal shift assay for target engagement
57	"FFPE Library Prep Methods" - - - -	21	FFPE Library Prep Methods
58
"Lung Cancer Classification and Targeting" - - - -	21	Lung Cancer Classification and Targeting
59	Immunotherapy biomarkers in cancer patients - - - -	20	Immunotherapy biomarkers in cancer patients
60	Colorectal cancer genomics and mutations - - - -	20	Colorectal cancer genomics and mutations
61	Epithelial-mesenchymal transition and plasticity in cancer - - - -	20	Epithelial-mesenchymal transition and plasticity in cancer
62	Electric fields for cancer treatment - - - -	19	Electric fields for cancer treatment
63	Cancer-associated fibroblasts in tumor microenvironment - - - -	19	Cancer-associated fibroblasts in tumor microenvironment
64
Prostate cancer research and diagnosis - - - -	19	Prostate cancer research and diagnosis
65
Acquired drug resistance and persister cells - - - -	19	Acquired drug resistance and persister cells
66
"EAC and Barrett's Esophagus Research" - - - -	19	EAC and Barrett's Esophagus Research
67
"Lung Cancer Research" - - - -	18	Lung Cancer Research
68
"Cachexia and Muscle Wasting in Cancer Patients" - - - -	18	Cachexia and Muscle Wasting in Cancer Patients
69	Cloud-based data governance for cancer research - - - -	17	Cloud-based data governance for cancer research
70	Ewing Sarcoma Research - - - -	17	Ewing Sarcoma Research
71
"Immunotherapy targeting Tregs" - - - -	16	Immunotherapy targeting Tregs
72
Nano-immunotherapy for cancer treatment - - - -	16	Nano-immunotherapy for cancer treatment
73
"Trial of T-1101 and T-1201 in Cancer Treatment" - - - -	16	Trial of T-1101 and T-1201 in Cancer Treatment
74	Radiation and Immunity in Cancer Treatment - - - -	16	Radiation and Immunity in Cancer Treatment
75	Immunotherapy and Neoantigens - - - -	15	Immunotherapy and Neoantigens
76	Aging and immune system in cancer - - - -	15	Aging and immune system in cancer
77
Progesterone and breast cancer - - - -	14	Progesterone and breast cancer
78
"Gut Microbiome in CRC Patients" - - - -	14	Gut Microbiome in CRC Patients
79	Hematopoiesis and Clonal Variants - - - -	14	Hematopoiesis and Clonal Variants
80
"Kinase Inhibition and Targeting" - - - -	14	Kinase Inhibition and Targeting
81	Paralog selective degraders for cancer therapy - - - -	13	Paralog selective degraders for cancer therapy
82
"Immunotherapy for Melanoma" - - - -	13	Immunotherapy for Melanoma
83	Genome-scale measurements for tumor normal benchmark - - - -	13	Genome-scale measurements for tumor normal benchmark
84	Immunotherapy for bladder cancer - - - -	13	Immunotherapy for bladder cancer
85	Hematopoietic Progenitor Kinase 1 Inhibition - - - -	13	Hematopoietic Progenitor Kinase 1 Inhibition
86
Variants of Uncertain Significance (VUS) - - - -	13	Variants of Uncertain Significance
87
"Colorectal cancer detection" - - - -	13	Colorectal cancer detection
88	Claudin18 Targeted Therapy - - - -	13	Claudin18 Targeted Therapy
89
"AI-based tumor purity analysis" - - - -	13	AI-based tumor purity analysis
90	Bispecific antibody development for cancer treatment - - - -	13	Bispecific antibody development for cancer treatment
91
"Genomic Variant Detection" - - - -	12	Genomic Variant Detection
92	Prostate cancer in African men - - - -	12	Prostate cancer in African men
93
"Microsatellite Instability and WRN Helicase Inhibition" - - - -	12	Microsatellite Instability and WRN Helicase Inhibition
94	Immunosuppression and antibody-enhancing drugs - - - -	12	Immunosuppression and antibody-enhancing drugs
95
"Immune Checkpoint Inhibitor Adverse Events" - - - -	12	Immune Checkpoint Inhibitor Adverse Events
96	Neuronal influence on cancer growth - - - -	12	Neuronal influence on cancer growth
97	"Uveal Melanoma and Selenoproteome Expression" - - - -	11	Uveal Melanoma and Selenoproteome Expression
98	HBV and HCC Treatment Studies - - - -	11	HBV and HCC Treatment Studies
99
Btk Inhibitors and Resistance Mechanisms - - - -	11	Btk Inhibitors and Resistance Mechanisms
100
"Tertiary Lymphoid Structures in Cancer Prognosis" - - - -	11	Tertiary Lymphoid Structures in Cancer Prognosis
101	Extrachromosomal DNA in cancer research - - - -	11	Extrachromosomal DNA in cancer research
102	Smarca2/4 degraders for cancer treatment - - - -	11	Smarca2/4 degraders for cancer treatment
103
"Epigenetic Regulators and Cancer Treatment" - - - -	11	Epigenetic Regulators and Cancer Treatment
104	Bispecific anti-egfr/cmet adc - - - -	11	Bispecific anti-egfr/cmet adc
105	Transposable elements and cancer - - - -	10	Transposable elements and cancer
106
"ER Degradation Therapy for Breast Cancer" - - - -	10	ER Degradation Therapy for Breast Cancer
107	Macrophage-based therapies in cancer - - - -	10	Macrophage-based therapies in cancer
108
"Genomic Alterations in NSCLC" - - - -	10	Genomic Alterations in NSCLC
109	Bladder Cancer Diagnosis and Monitoring - - - -	10	Bladder Cancer Diagnosis and Monitoring
110
"Genomic profiling for cancer diagnosis" - - - -	10	Genomic profiling for cancer diagnosis
111	TCR Repertoire in Cancer Patients - - - -	10	TCR Repertoire in Cancer Patients
112	Kras Vaccine Development - - - -	10	Kras Vaccine Development
113
"G-quadruplex Targeting Compound in Pancreatic Cancer Treatment" - - - -	9	G-quadruplex Targeting Compound in Pancreatic Cancer Treatment
114
Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC) - - - -	9	Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer
115	Liquid biopsy for glioma monitoring - - - -	9	Liquid biopsy for glioma monitoring
116
Mismatch repair and immune checkpoint inhibitors - - - -	9	Mismatch repair and immune checkpoint inhibitors
117
"Immunomodulatory effects of mushroom consumption in prostate cancer." - - - -	9	Immunomodulatory effects of mushroom consumption in prostate cancer.
118	Nectin-4 targeted ADCs - - - -	9	Nectin-4 targeted ADCs
119	Single-cell gene expression technologies - - - -	9	Single-cell gene expression technologies
120
Head and neck cancer subtyping - - - -	9	Head and neck cancer subtyping
121	Cancer Vaccine Development - - - -	8	Cancer Vaccine Development
122	Proteomic analysis of cancer tissues - - - -	8	Proteomic analysis of cancer tissues
123
"Lymphoma Prognostics and Treatment Strategies" - - - -	8	Lymphoma Prognostics and Treatment Strategies
124
"Chemotherapy Resistance Mechanisms in Colorectal Cancer" - - - -	8	Chemotherapy Resistance Mechanisms in Colorectal Cancer
125	Cancer-associated fibroblasts research - - - -	7	Cancer-associated fibroblasts research
126
Condensate-based drug discovery - - - -	7	Condensate-based drug discovery
127
"Metabolism and Cancer Treatment" - - - -	7	Metabolism and Cancer Treatment
128	Stat3 degraders for cancer therapy - - - -	7	Stat3 degraders for cancer therapy
129	Melanoma research and embryonic development - - - -	7	Melanoma research and embryonic development
130
"Ovarian Cancer Biomarkers" - - - -	7	Ovarian Cancer Biomarkers
131
LncRNA and Promoter Regulation in Cancer - - - -	7	LncRNA and Promoter Regulation in Cancer
132	Immunotherapy in cancer treatment - - - -	7	Immunotherapy in cancer treatment
133
"Ferroptosis in Cancer Cells" - - - -	7	Ferroptosis in Cancer Cells
134
"Cdk4 Inhibitors and Breast Cancer Resistance" - - - -	7	Cdk4 Inhibitors and Breast Cancer Resistance
135	Radiation therapy and DNA damage response inhibitors - - - -	7	Radiation therapy and DNA damage response inhibitors
136	Liquid biopsy for cancer diagnosis and treatment response. - - - -	7	Liquid biopsy for cancer diagnosis and treatment response.
137	Brain Metastasis Survival Analysis - - - -	7	Brain Metastasis Survival Analysis
138
Molecular Biomarkers in Breast Cancer - - - -	7	Molecular Biomarkers in Breast Cancer
139
P53 and RPL22 in Cancer - - - -	7	P53 and RPL22 in Cancer
140	Colorectal cancer research - - - -	7	Colorectal cancer research
141
"Tumor Suppression Mechanisms" - - - -	7	Tumor Suppression Mechanisms
142	Radiation-induced salivary gland damage and regeneration - - - -	7	Radiation-induced salivary gland damage and regeneration
143
"Adenosine Signaling and Immunotherapy" - - - -	7	Adenosine Signaling and Immunotherapy
144	Sarcopenia and ICI in NSCLC - - - -	7	Sarcopenia and ICI in NSCLC
145	Ethnic disparities in lymphoma survival - - - -	7	Ethnic disparities in lymphoma survival
146	Liquid biopsy for lung cancer screening - - - -	7	Liquid biopsy for lung cancer screening
147
"KDM6A Loss in Urothelial Carcinomas" - - - -	7	KDM6A Loss in Urothelial Carcinomas
148	Immuno-oncology screens with CRISPR and RNA-seq - - - -	6	Immuno-oncology screens with CRISPR and RNA-seq
149	P53 Restoration Therapy - - - -	6	P53 Restoration Therapy
150	Immunometabolic targeting in cancer immunotherapy - - - -	6	Immunometabolic targeting in cancer immunotherapy
151
"Breast cancer recurrence and gene regulation" - - - -	6	Breast cancer recurrence and gene regulation
152	Head and neck squamous cell carcinoma (HNSCC) research - - - -	6	Head and neck squamous cell carcinoma research
153
"HCC Immune Cells Study" - - - -	6	HCC Immune Cells Study
154
"Pd-L1 IHC Scoring Methods" - - - -	6	Pd-L1 IHC Scoring Methods
155	Ovarian Cancer Glycosylation and Metastasis - - - -	6	Ovarian Cancer Glycosylation and Metastasis
156
"Ubiquitin-Proteasome System in Cancer Treatment" - - - -	6	Ubiquitin-Proteasome System in Cancer Treatment
157
Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma - - - -	6	Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma
158	Immunotherapy in Non-Small Cell Lung Cancer - - - -	6	Immunotherapy in Non-Small Cell Lung Cancer
159	Anlotinib + Chemo for Advanced Escc Treatment - - - -	6	Anlotinib + Chemo for Advanced Escc Treatment
160
"Myc Targeting Technologies" - - - -	6	Myc Targeting Technologies
161	Neuroblastoma Epigenetics Study - - - -	5	Neuroblastoma Epigenetics Study
162
"Metastasis and Genetic Alterations" - - - -	5	Metastasis and Genetic Alterations
163	T Cell Exhaustion and Stemness Programs - - - -	5	T Cell Exhaustion and Stemness Programs
164
Prostate cancer research - - - -	5	Prostate cancer research
165
"Lung Cancer Microenvironment Analysis" - - - -	5	Lung Cancer Microenvironment Analysis
166
"Pi3k/Akt Inhibitors in Breast Cancer" - - - -	5	Pi3k/Akt Inhibitors in Breast Cancer
167
"Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis" - - - -	5	Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis
168	Extracellular Vesicle Research in Ovarian Cancer - - - -	5	Extracellular Vesicle Research in Ovarian Cancer
169	Colorectal Cancer Secondary Malignancies in Young Adults - - - -	5	Colorectal Cancer Secondary Malignancies in Young Adults
170	Molecular Glues Targeting Cancer-Specific E3 Ligases - - - -	5	Molecular Glues Targeting Cancer-Specific E3 Ligases
171	Epigenetics and Cancer Research - - - -	5	Epigenetics and Cancer Research
172	Immunogenic neoantigens and NMD inhibition in cancer immunotherapy - - - -	5	Immunogenic neoantigens and NMD inhibition in cancer immunotherapy
173	Click Activated Prodrugs Against Cancer Platform - - - -	5	Click Activated Prodrugs Against Cancer Platform